Clinical Spotlight is a HistoIndex newsletter series that explores topics in MASH, clinical diagnostics, and chronic liver disease management. Each edition provides commentary based on evidence from relevant publications and the latest research developments. The emergence of FDA-approved treatments for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis (F2–F3) marks an important milestone in hepatology. However, […]

As Metabolic Dysfunction-associated Steatohepatitis (MASH) continues to rise in both clinical prevalence and therapeutic focus, the demand for accurate, reproducible, and scalable fibrosis assessment has intensified. Fibrosis remains the most critical histological feature for staging disease severity, predicting outcomes, and evaluating treatment response. Traditionally, liver biopsy evaluation has relied on expert interpretation, an approach that,

Diagnosing and staging Metabolic Dysfunction-Associated Steatohepatitis (MASH) has become one of the most pressing challenges in hepatology today. As the prevalence of MASH rises globally, now recognized as a progressive form of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), the demand for accurate, scalable diagnostic tools is intensifying. With the conditional approval of therapies such as